Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: December 1, 2004
Last updated: October 30, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2006
  Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)